Buy SDA (3-4-methylenethiooxyamphetamine) Cas 101-77-9

SDA, also known as 3,4-methylenethiooxyamphetamine (3T-MDA), is a putative entactogen and psychedelic drug of the phenethylamine and amphetamine families related to 3,4-methylenedioxyamphetamine (MDA).^[1][2] It is the analogue of MDA in which the oxygen atom at the 3 position within the 3,4-methylenedioxy substitution has been replaced with a sulfur atom to give a 1,3-benzoxathiole rather than 1,3-benzodioxole ring system.^[1][2] The drug is also the N–desmethyl analogue of 3,4-methylenethiooxy-N-methylamphetamine (SDMA; 3T-MDMA).^[1]

Similarly to MDA, SDA is a serotonin–norepinephrine–dopamine releasing agent (SNDRA) and a non-selective serotonin 5-HT₂ receptor agonist.^[1] However, SDA was 16-fold more potent as a serotonin releaser, 16-fold more potent as a dopamine releaser, and 2-fold more potent as a norepinephrine releaser than MDA in HEK293 cells in vitro.^[1] In addition, it was 2- to 3-fold more potent as an agonist of the serotonin 5-HT_2A, 5-HT_2B, and 5-HT_2C receptors than MDA.^[1] SDA had largely similar activational efficacies at the serotonin 5-HT₂ receptors as MDA.^[1] Due to its greater potency as a monoamine releasing agent, SDA may be active at lower doses or concentrations than MDA.^[1]

SDA produced hyperlocomotion and hyperthermia in rodents and to a greater extent than SDMA or MDMA.^[1] However, SDA did not produce significant rewarding effects in the conditioned place preference (CPP) paradigm unlike MDMA but similarly to SDMA.^[1] Hence, SDA might have reduced misuse potential compared to other related drugs like MDMA.^[1] Similarly to findings with MDA, SDA produced the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, and hence may produce hallucinogenic effects in humans.^[1] Unlike SDMA and MDMA, SDA produced thigmotaxis in the open field test, an anxiety-like effect.^[1] SDA may be cardiotoxic due to serotonin 5-HT_2B receptor agonism.^[1]